Real‐world effectiveness and safety of tildrakizumab in long‐term treatment of plaque psoriasis: Results from the non‐interventional, prospective, multicentre study TILOT

BACKGROUND: Plaque psoriasis is a chronic inflammatory disorder affecting the skin and impacting quality of life. Tildrakizumab (TIL) is an IL‐23 inhibitor licensed for moderate‐to‐severe plaque psoriasis. Regulatory approval of medicinal products is based on safety and efficacy data from randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsianakas, Athanasios, Schwichtenberg, Uwe, Pierchalla, Peter, Hinz, Torsten, Diemert, Sebastian, Korge, Bernhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles and Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087575/
https://www.ncbi.nlm.nih.gov/pubmed/36066998
http://dx.doi.org/10.1111/jdv.18572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087575/
https://www.ncbi.nlm.nih.gov/pubmed/36066998
http://dx.doi.org/10.1111/jdv.18572

Ejemplares similares